Ideas Discussions Themes Map Live Ask AI

All beneficiaries

company

Supernus Pharmaceuticals

Information not available.

No information was found regarding Supernus Pharmaceuticals in the provided research brief.

Ideas that could help Supernus Pharmaceuticals

GABA-Flag: A Pre-Stimulant Non-Responder Test for ADHDWhy it helps: Markets Qelbree, a non-stimulant ADHD medication; a validated test that identifies likely stimulant non-responders routes patients to non-stimulant treatment earlier, expanding its eligible population.
KI-Hyperactivity Model and Dopamine Endpoint Suite for ADHD Drug ScreeningWhy it helps: Markets the non-stimulant Qelbree and needs models that measure dopaminergic and synaptic rescue, not just locomotion, to differentiate mechanisms of new candidates.
Blinded-Rater-as-a-Service for ADHD Intervention TrialsWhy it helps: Markets viloxazine (Qelbree), named among the key non-stimulants in the trial landscape; probably-blinded central raters strengthen its ongoing pediatric and adult ADHD trial program against placebo-rating inflation.
Rigid-DMN Flag: A Resting-State Response-Control Marker for Pediatric ADHDWhy it helps: Develops ADHD therapies (Qelbree); a validated stratification biomarker for response-control deficits helps enrich pediatric trials with impulsive-error-prone participants and supports inhibition endpoints.
Comorbidity Mechanism Testing Service for Longitudinal Symptom DataWhy it helps: Its ADHD portfolio (Qelbree, Mydayis) serves pediatric populations where comorbidity is the norm; a mechanism verdict tells its clinical development team whether comorbid symptoms are credible secondary endpoints in trials.

Recent research, turned into concrete, commercially plausible innovation ideas — each with an interactive prototype you can try.

Explore

Ideas
Discussions
Themes
Live
Research
Map
Personas
Who benefits
Ask AI

For you

For researchers
For industry
For investors

Learn more

About
How it works
FAQ

Account

Sign in
Your space
Your stream
Your digest
Your contexts
Your data

© 2026 SeedlabsRecent research, turned into shippable ideas.